RE:Plasmid pDC316 (mbx) ebola drugThanks for the link, I was busy earlier and didn't notice the link you posted.....and judged you too quickly by your 67 ignores. So yeah, Purdue University actually has developed a first generation vaccine they tested against Ebola that failed to show any efficacy.....still not something I would say gives out company any strength in the Ebloa market (quoted from USDA link you provided): https://www.reeis.usda.gov/web/crisprojectpages../0215991-recombinant-vaccines-for-porcine-reproductive-and-respiratory-syndrome.html Pigs were humanely euthanized on day 21 post-challenge for necropsy examination and collection of tissue samples for histopathology and quantization of PRRS viral RNA by quantitative PCR. Serum samples collected from pigs of all three groups on days 0, 21 and 35 post-vaccination tested negative by Herd-Check ELISA and virus neutralization. Serum samples collected on days 21 and 35 post-vaccination from pigs in group C contained high levels of IgG antibodies against the recombinant Ebola viral protein. Following challenge, 2 pigs in group A, 3 pigs in group B and 4 pigs in group C exhibited mild dyspnea, mild erythema and occasional coughing. Serum samples collected on days 10, 15 and 21 post-challenge contained similar levels of PRRSV-specific antibodies by Herd-check ELISA. All post-challenge serum samples contained similar quantities of PRRS viral RNA. Histological examination of the lungs and lymph nodes also did not reveal any difference between the vaccinated and the control groups, and the findings were consistent with the presence of PRRS viral infection in the examined tissues. Future experiments will focus on increasing the level of 456 synthetic protein in hAD5 and using the prime-boost immunization strategy to stimulate a better antigen-specific immunity.